Skip to main content

Evaluation of Late Effects and Natural History of Disease in Patients Treated With Radiotherapy

Trial Status: Active

Background: - This protocol acknowledges that it is in the interest of the NIH and ROB, as well as our patients, to continue to follow those who have been treated with radiotherapy at ROB and are not otherwise eligible for current active research protocols. - It also provides a mechanism for the correlation and interpretation of disparate data for research into the long term side effects and outcomes for a variety of disease entities and treatments, such as combined modality treatment, MoAb, PDT, radiation modifiers, intraoperative radiotherapy, etc. Objective: -The primary objective of this protocol is to assess the late effects of treatment and the natural history of disease through collection of data from any standard procedures performed as part of follow up care on patients previously treated with radiotherapy in the Radiation Oncology Branch (ROB). Eligibility: -Patients who received radiation therapy at the NCI and are not entered on an interventional research protocol at the time of enrollment. Design: - This is a natural history protocol in which data will be collected from Radiation Oncology Branch patients receiving standard of care long-term follow up care and evaluation, including NIH consultation services as required. - It will be made clear to patients in the consent form, that data collected during their follow-up may be used anonymously for publications concerning the natural history of disease processes and long-term effects of treatment.

Inclusion Criteria

  • - INCLUSION CRITERIA: ROB investigator deems that it is in the best interests of the participant and the NCI/ROB for the participant to be seen in follow-up in the ROB clinic. Participant is able to provide informed consent. Participant must have a primary physician in the community to whom records and appropriate follow-up management can be given. Social services will be enlisted for any participants who lack health insurance, etc. Participants who have received radiotherapy in the ROB and may or may not be officially entered on a clinical protocol. Some participants treated prior to 1993 may not have been officially entered on a clinical protocol. Age greater than or equal to 18 years of age EXCLUSION CRITERIA: Participants who are on an interventional research protocol at NIH at the time of enrollment.

Maryland

Bethesda
National Institutes of Health Clinical Center
Status: ACTIVE
Contact: National Cancer Institute Referral Office
Phone: 888-624-1937

BACKGROUND

- This protocol acknowledges that it is in the interest of the NIH and ROB, as well as our

participants, to continue to follow those who have been treated with radiotherapy at ROB

and are not otherwise eligible for current active research protocols.

- It also provides a mechanism for the correlation and interpretation of disparate data

for research into the long term side effects and outcomes for a variety of disease

entities and treatments, such as combined modality treatment, MoAb, PDT, radiation

modifiers,

intraoperative radiotherapy, etc.

OBJECTIVE

-The primary objective of this protocol is to assess the late effects of treatment and the

natural history of disease through collection of data from any standard procedures performed

as part of follow up care on participants previously treated with radiotherapy in the

Radiation Oncology Branch (ROB).

ELIGIBILITY

-Participants who received radiation therapy at the NCI and are not enrolled on an

interventional research protocol at the time of enrollment.

DESIGN

- This is a natural history protocol in which data will be collected from Radiation

Oncology Branch participants receiving standard of care long-term follow up care and

evaluation, including NIH consultation services as required.

- It will be made clear to participants in the consent form, that data collected during

their follow-up may be used anonymously for publications concerning the natural history

of disease processes and long-term effects of treatment.

Trial Phase Phase NA

Trial Type Not provided by clinicaltrials.gov

Lead Organization
National Cancer Institute

Principal Investigator
Kevin Camphausen

  • Primary ID 000074
  • Secondary IDs NCI-2018-02310, 00-C-0074, NCI-2015-01189
  • Clinicaltrials.gov ID NCT00026650